| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/BF01061994 |
| P698 | PubMed publication ID | 10603506 |
| P2093 | author name string | Cannon CP | |
| Becker RC | |||
| P2860 | cites work | Experimental studies on a recombinant hirudin, CGP 39393 | Q70202668 |
| Pharmacological studies on the antithrombotic action of hirudin in experimental animals | Q70439861 | ||
| Inhibition of the thrombin-platelet reaction by hirudin | Q71392199 | ||
| Isolation of hirudin from medicinal leech | Q71987833 | ||
| A quantitative thrombin time for determining levels of hirudin and Hirulog | Q72262042 | ||
| A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial | Q72332452 | ||
| Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial | Q72344112 | ||
| Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial | Q72360950 | ||
| Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters | Q72560551 | ||
| Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty | Q72560573 | ||
| An international collaborative study to investigate standardisation of hirudin potency | Q72808552 | ||
| [Studies on the mechanism of the anticoagulant effect of hirudin] | Q74342146 | ||
| [Isolation and chemical characterization of hirudin] | Q74652077 | ||
| [Purification of hirudin.] | Q79539876 | ||
| [Use of hirudin in clinical coagulation laboratories] | Q93693805 | ||
| Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial | Q33382347 | ||
| Biochemistry and genetic engineering of hirudin | Q38735186 | ||
| Purification of hirudin by the method of isoelectric focusing | Q39143577 | ||
| Comparison of the inhibition of thrombin by three plasma protease inhibitors | Q39500526 | ||
| A large fragment approach to DNA synthesis: total synthesis of a gene for the protease inhibitor eglin c from the leech Hirudo medicinalis and its expression in E. coli. | Q40461418 | ||
| Binding of thrombin to human platelet plasma membranes | Q41947098 | ||
| Fibrin, red cell and platelet interactions in an experimental model of thrombosis | Q42063747 | ||
| Binding of thrombin to human platelets and its possible significance | Q44612319 | ||
| Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin-thrombin interaction | Q45083166 | ||
| Kinetics of the thrombin-induced release of calcium(II) by platelets | Q48017967 | ||
| The complete covalent structure of hirudin. Localization of the disulfide bonds | Q49239525 | ||
| Kinetics of the inhibition of thrombin by hirudin. | Q52630061 | ||
| The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. | Q53824140 | ||
| Purification and analysis of the thrombin inhibitor hirudin | Q53878501 | ||
| Purification and biochemical characterization of recombinant hirudin produced by Saccharomyces cerevisiae. | Q54731380 | ||
| Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. | Q54743556 | ||
| Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase | Q55489690 | ||
| Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group | Q58898563 | ||
| The structural elements of hirudin which bind to the fibrinogen recognition site of thrombin are exclusively located within its acidic C-terminal tail | Q67275722 | ||
| Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin | Q67976386 | ||
| Clinico-pharmacological studies with recombinant hirudin | Q68026562 | ||
| Pharmacology of r-hirudin in renal impairment | Q68037221 | ||
| The influence of GAP promoter variants on hirudin production, average plasmid copy number and cell growth in Saccharomyces cerevisiae | Q68579429 | ||
| Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats | Q68837645 | ||
| Prevention of experimental coronary thrombosis by hirudin | Q69041714 | ||
| Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin | Q70018756 | ||
| Assay of hirudin in plasma using a chromogenic thrombin substrate | Q70066031 | ||
| Hirudin insensitive thrombin-stimulated platelet release | Q70079764 | ||
| P433 | issue | 1 | |
| P921 | main subject | hirudin | Q386715 |
| P304 | page(s) | 7-16 | |
| P577 | publication date | 1994-01-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Hirudin: Its Biology and Clinical Use | |
| P478 | volume | 1 |
Search more.